Collegium Reports Fourth Quarter and Full-Year 2021 Financial Results
– BDSI Acquisition Expected to Close Late Q1 2022 –
– 2022 Revenue Guidance of
– Cash Balance of
– Conference Call Scheduled for Today at
“We strengthened the fundamentals of our pain portfolio in the face of challenging market dynamics throughout 2021, achieved key operational objectives, and completed a restructuring that positions Collegium to embark upon a period of growth and value creation,” said
“We exited 2021 in a strong financial position,” said
Business Highlights for 2021
- Achieved the largest market share increase for Xtampza ER since its first full year of launch, with an exit share of 33% of the oxycodone extended-release market, an 8-percentage point increase versus 2020.
- Leveraged our cost structure by containing the increase in GAAP operating expense to less than 10%. When GAAP operating expenses are adjusted for stock-based compensation, restructuring, and litigation, the adjusted operating expenses were flat versus 2020.
- Executed a corporate restructuring in the fourth quarter of 2021, positioning the Company to maximize the potential of its portfolio and to efficiently absorb a commercial stage, high-synergy acquisition.
- Transitioned to a dedicated manufacturing suite for Xtampza ER and filed a Prior Approval Supplement for an alternate Nucynta® ER manufacturing site in
December 2021. We expect transition of supply and benefit to cost of production to begin in the second half of 2022 and expect to realize full cost savings in 2023.
$42.9 millionto shareholders through share repurchase and repaid $50.0 millionof debt.
- Announced settlement framework to resolve pending opioid litigation.
- Received recognition of our strong corporate culture through the Boston Globe Top Places to Work and National Top Workplaces awards.
2021 Revenue Adjustment
Provisions for product returns are based on product-level returns rates, recent in-process returns claims, as well as relevant market events and other factors. The Company’s returns policy, for compliance and financial reporting purposes, requires that product is physically returned within an 18-month window beginning 6 months prior to expiration and up until 12 months after expiration.
During the year ended
In addition, the delay in processing returns resulted in a significant portion of the returns claimed not being physically returned within the time period required by the Company’s returns policy, thereby rendering them ineligible for credit. The Company has engaged with its customers to collect amounts due for unprocessed return claims that are not eligible for refund due to the expiration of the return rights, and expects to pursue such collections vigorously, inclusive of litigation if necessary.
During the fourth quarter, after significant and sustained efforts with customers to resolve the unprocessed return claims, the Company formally denied a significant portion of these claims under the Company’s return policy and also concluded that the returns rate had increased. Although the Company has denied and expects to continue to deny credit for product returns that are not in accordance with its return policy, uncertainty exists related to the ultimate resolution of these claims.
As a result of this uncertainty, as well as the impact of unprocessed claims on estimates of future returns, the Company recorded an adjustment to reduce product revenue, net of
Financial Results for the Fourth Quarter Ended
- Total net product revenues were
$27.4 millionfor the quarter ended December 31, 2021(the “2021 Quarter”), compared to $76.3 millionfor the quarter ended December 31, 2020(the “2020 Quarter”). Total net product revenues in the 2021 Quarter include a $38.3 millionproduct revenue adjustment related to returns adjustments as described above.
- Xtampza ER net product revenues were
$5.3 millionfor the 2021 Quarter, which includes returns adjustments of $13.8 millionas described above. Xtampza ER net product revenues were $30.8 millionin the 2020 Quarter.
- Nucynta franchise net product revenues were
$22.1 millionfor the 2021 Quarter, which includes returns adjustments of $24.5 millionas described above. Nucynta franchise net product revenues were $45.5 millionfor the 2020 quarter.
- GAAP operating expenses were
$32.8 millionfor the 2021 Quarter, compared to $29.3 millionfor the 2020 quarter. Adjusted operating expenses, which exclude stock-based compensation of $4.9 million, restructuring expenses of $4.6 million, and litigation settlements of $2.9 million, were $20.4 millionfor the 2021 Quarter, compared to $23.1 millionfor the 2020 Quarter.
- Net loss for the 2021 Quarter was
($25.0) million, or ( $0.73) loss per share (basic and diluted), compared to net income of $7.0 million, or $0.20earnings per share (basic and diluted), for the 2020 Quarter. Net loss for the 2021 Quarter and net income for the 2020 Quarter included stock-based compensation expense of $4.9 millionand $6.2 million, respectively.
- Adjusted EBITDA for the 2021 Quarter was
($4.5) million, compared to $38.3 millionfor the 2020 Quarter.
Full-Year 2021 Financial Highlights
- Total net product revenues were
$276.9 millionfor the year ended December 31, 2021(the “FY 2021”), compared to $310.0 millionfor the year ended December 31, 2020(the “FY 2020”). Total net product revenues in FY 2021 include a $38.3 millionproduct revenue adjustment related to returns adjustments.
- Xtampza ER net product revenues were
$103.7 millionfor FY 2021, which includes a $13.8 millionproduct revenue adjustment related to returns adjustments. Xtampza ER product revenues, net were $128.0 millionfor FY 2020.
- Nucynta franchise net revenues were
$173.2 millionfor FY 2021, which includes a $24.5 millionadjustment related to returns adjustments. Nucynta franchise net revenues were $182.0 millionfor FY 2020.
- GAAP operating expenses were
$133.0 millionfor FY 2021, compared to $123.6 millionfor FY 2020. Adjusted operating expenses, which exclude stock-based compensation of $24.3 million, restructuring expenses of $4.6 million, and litigation settlements of $2.9 million, were $101.2 millionfor FY 2021, compared to $101.7 millionfor FY 2020.
- Net income was
$71.5 million, or $2.05earnings per share (basic) and $1.86earnings per share (diluted), for FY 2021, compared to net income of $26.8 million, or $0.78earnings per share (basic) and $0.76earnings per share (diluted), for FY 2020. Net income included stock-based compensation expense of $24.3 millionand $21.9 millionfor FY 2021 and FY 2020, respectively.
- Adjusted EBITDA for FY 2021 was
$118.3 million, compared to $139.7 millionfor FY 2020.
- The Company exited FY 2021 with a cash balance of
Financial Guidance for 2022
- Total revenues are expected in the range of
$315 millionto $330 million
The Company expects to provide a more detailed outlook for 2022 after the closing of the Company’s acquisition of BioDelivery Sciences International, Inc. (“BDSI”), which is expected to occur late in the first quarter of 2022, subject to the satisfaction of customary closing conditions.
Conference Call Information
The Company will host a conference call and live audio webcast on
Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in
Non-GAAP Financial Measures
To supplement our financial results presented on a GAAP basis, we have included information about certain non-GAAP financial measures such as adjusted EBITDA and adjusted operating expenses. We use these non-GAAP financial measures to understand, manage and evaluate our business as we believe they provide additional information on the performance of our business. We believe that the presentation of these non-GAAP financial measures, taken in conjunction with our results under GAAP, provide analysts, investors, lenders and other third parties insight into our view and assessment of our ongoing operating performance. In addition, we believe that the presentation of these non-GAAP financial measures, when viewed with our results under GAAP and the accompanying reconciliations, provide supplementary information that may be useful to analysts, investors, lenders, and other third parties in assessing our performance and results from period to period. We report these non-GAAP financial measures to portray the results of our operations prior to considering certain income statement elements. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, net income or other financial measures calculated in accordance with GAAP.
Adjusted EBITDA is a non-GAAP financial measure that represents GAAP net income adjusted to exclude interest expense, interest income, the benefit from or provision for income taxes, depreciation, amortization, stock-based compensation, restructuring expenses, and litigation settlements. Adjusted EBITDA, as used by us, may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.
There are several limitations related to the use of adjusted EBITDA rather than net income, which is the nearest GAAP equivalent, such as:
- adjusted EBITDA excludes depreciation and amortization, and, although these are non-cash expenses, the assets being depreciated or amortized may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA;
- we exclude stock-based compensation expense from adjusted EBITDA although (a) it has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy and (b) if we did not pay out a portion of our compensation in the form of stock-based compensation, the cash salary expense included in operating expenses would be higher, which would affect our cash position;
- adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs;
- adjusted EBITDA does not reflect the benefit from or provision for income taxes or the cash requirements to pay taxes;
- adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments;
- we exclude restructuring expenses from adjusted EBITDA. Restructuring expenses primarily include employee severance and contract termination costs. The amount and/or frequency of these restructuring expenses are not part of our underlying business; and
- we exclude litigation settlements from adjusted EBITDA, as well as any applicable income items or credit adjustments due to subsequent changes in estimates. This does not include our legal fees to defend claims, which are expensed as incurred.
Adjusted operating expenses is a non-GAAP financial measure that represents GAAP operating expenses adjusted to exclude stock-based compensation expense, restructuring, and litigation settlements.
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements related to the acquisition of BioDelivery Sciences International, Inc. (“BDSI”) and the anticipated timing and benefits thereof, our strategy, plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential, potential synergies, anticipated product portfolio, development programs, patent terms and other statements that are not historical facts. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the company's current expectations. Actual results may differ materially from management’s expectations and such forward-looking statements in this press release could be affected as a result of various important factors, including risks relating to, among others: risks related to our ability to complete the transaction on the proposed terms and schedule or at all; whether the tender offer conditions will be satisfied, including whether sufficient stockholders of BDSI tender their shares in the transaction; the outcome of legal proceedings that may be instituted against BDSI and/or others relating to the transaction; the failure (or delay) to receive the required regulatory approvals relating to the transaction; the possibility that competing offers will be made; risks related to the ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the transaction making it more difficult to maintain business and operational relationships; negative effects of this announcement or the consummation of the proposed acquisition on the market price of our common stock and/or operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the proposed acquisition; risks related to future opportunities and plans for BDSI and its products, including uncertainty of the expected financial performance of BDSI and its products; the impact of the COVID-19 pandemic on our ability to conduct our business, reach our customers, and supply the market with our products; our ability to commercialize and grow sales of our products; our ability to manage our relationships with licensors; the success of competing products that are or become available; our ability to obtain and maintain regulatory approval of our products and any product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product; the size of the markets for our products and product candidates, and our ability to service those markets; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products and product candidates; the costs of commercialization activities, including marketing, sales and distribution; changing market conditions for our products; the outcome of any patent infringement, opioid-related or other litigation that may be brought by or against us, including litigation with
Head of Investor Relations and Corporate Communications
|Unaudited Selected Consolidated Balance Sheet Information|
|Cash and cash equivalents||$||186,426||$||174,116|
|Accounts receivable, net||105,844||83,320|
|Prepaid expenses and other current assets||5,879||4,838|
|Property and equipment, net||19,491||18,988|
|Operating lease assets||7,644||8,391|
|Intangible asset, net||268,723||335,904|
|Deferred tax assets||78,042||—|
|Other noncurrent assets||87||123|
|Accounts payable and accrued expenses||33,403||34,672|
|Accrued rebates, returns and discounts||196,996||156,554|
|Term notes payable||110,019||157,514|
|Convertible senior notes||139,966||99,575|
|Operating lease liabilities||8,765||9,495|
|Total liabilities and stockholders’ equity||$||692,077||$||643,841|
|Unaudited Condensed Statements of Operations|
|(in thousands, except share and per share amounts)|
|Three months ended
|Product revenues, net||$||27,362||$||76,271||$||276,868||$||310,016|
|Cost of product revenues|
|Cost of product revenues (excluding intangible asset amortization)||11,900||15,184||59,070||69,500|
|Intangible asset amortization||16,795||16,795||67,181||60,680|
|Total cost of products revenues||28,695||31,979||126,251||130,180|
|Research and development||1,609||2,472||9,451||9,772|
|Selling, general and administrative||26,602||26,824||118,960||113,832|
|Total operating expenses||32,789||29,296||132,989||123,604|
|(Loss) income from operations||(34,122||)||14,996||17,628||56,232|
|(Loss) income before income taxes||(38,876||)||7,262||(3,374||)||27,582|
|(Benefit from) Provision for income taxes||(13,842||)||304||(74,891||)||830|
|Net (loss) income||$||(25,034||)||$||6,958||$||71,517||$||26,752|
|(Loss) earnings per share — basic||$||(0.73||)||$||0.20||$||2.05||$||0.78|
|Weighted-average shares — basic||34,123,309||34,592,277||34,936,817||34,407,959|
|(Loss) earnings per share — diluted||$||(0.73||)||$||0.20||$||1.86||$||0.76|
|Weighted-average shares — diluted||34,123,309||35,417,623||41,045,805||35,151,353|
|Reconciliation of GAAP Net Income to Adjusted EBITDA|
|Three months ended
|GAAP net (loss) income||$||(25,034||)||$||6,958||$||71,517||$||26,752|
|Provision for (benefit from) income taxes||(13,842||)||304||(74,891||)||830|
|Stock-based compensation expense||4,912||6,210||24,255||21,910|
|Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses|
|Three months ended
|GAAP Operating expenses||$||32,789||$||29,296||$||132,989||$||123,604|
|Adjusted operating expenses||$||20,364||$||23,086||$||101,221||$||101,694|
Source: Collegium Pharmaceutical, Inc.